Veracyte, Inc. (VCYT)
Veracyte, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $45.43, down 6.41% on the session, giving a market capitalisation of $3.62B. On trailing twelve-month figures it carries a trailing P/E of 31.55, a net margin of 20.4%. Its beta of 1.93 implies it has historically moved more than the broad market.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte, Inc. is most often compared with the following Healthcare names: